Effect of sodium–glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus

Table 2 Changes in lipids parameters at 24 weeks between groups with different treatment.

Parameters	SGLT2 inhibitor (n = 19)			Placebo (n = 10)			P-value b/w group at 24 weeks
Parameters	Baseline	24 weeks	P-value	Baseline	24 weeks	P-value	P-value b/w group at 24 weeks
TC (mmol/L)	4.88 ± 0.89	5.12 ± 0.85	0.061	4.75 ± 2.18	4.79 (3.77, 5.31)	0.785	0.094
TG (mmol/L)	1.71 (0.98, 3.40)	1.16 ± 0.56	0.020	1.23 (1.04, 2.96)	5.00 ± 1.78	0.878	0.501
LDL-C (mmol/L)	2.93 ± 0.83	3.15 ± 0.75	0.108	2.342 ± 0.62	1.94 ± 0.54	0.990	0.379
HDL-C (mmol/L)	1.28 ± 0.27	1.68 ± 0.39	< 0.001	1.15 ± 0.31	1.24 ± 0.25	0.173	0.012

TC total cholesterol, TG triglyceride, LDL-C low density lipoprotein-cholesterol, HDL-C high density lipoprotein-cholesterol, SGLT2 sodium–glucose co-transporter-2

ISSN: 1758-5996